Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
17
NMRD Quote, Financials, Valuation and Earnings
Last price:
$0.0001
Seasonality move
:
2.01%
Day range:
$0.0001 - $0.0002
52-week range:
$0.0000 - $0.0500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.2K
Avg. volume:
6.3K
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Nemaura Medical, Inc. has 149999900% upside to fair value with a price target of -- per share.
NMRD vs. S&P 500
-
Over the past 5 trading days, Nemaura Medical, Inc. has underperformed the S&P 500 by -100% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nemaura Medical, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nemaura Medical, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Nemaura Medical, Inc. reported revenues of --.
Earnings Growth
-
Nemaura Medical, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nemaura Medical, Inc. reported earnings per share of --.
Enterprise value:
19.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.00x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $183.6K | $397.3K | -- | $3K | -- | |
| Gross Profit | -$100.2K | -$208.6K | -$485.3K | -$95.9K | -$80.4K | |
| Operating Income | -$6.6M | -$8.7M | -$9.3M | -$1.6M | -$1.5M | |
| EBITDA | -$6.4M | -$8.4M | -$8.8M | -$1.5M | -$1.5M | |
| Diluted EPS | -$0.53 | -$0.54 | -$0.38 | -$0.07 | -$0.07 | |
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.7M | $16.6M | $25.1M | $10.9M | $4.4M | |
| Total Assets | $2.2M | $17.6M | $27.1M | $13M | $5.2M | |
| Current Liabilities | $1.1M | $4.4M | $16.1M | $13.2M | $23M | |
| Total Liabilities | $2.4M | $7.3M | $26.1M | $22.8M | $23M | |
| Total Equity | -$234.5K | $10.3M | $1M | -$9.9M | -$17.8M | |
| Total Debt | -- | $5.3M | $23.6M | $20.1M | $19.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.7M | -$8.2M | -$9.6M | -$1.5M | -$1.5M | |
| Cash From Investing | -$1.2M | -$515.3K | -$177.2K | -$57.6K | -$10.4K | |
| Cash From Financing | $15.1M | -$6.2M | $2.7M | -$1.7M | -$3M | |
| Free Cash Flow | -$6.9M | -$8.8M | -$9.7M | -$1.6M | -$1.5M | |
NMRD
Sector
Market Cap
--
$27.9M
Price % of 52-Week High
0%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
--
-16.66%
Beta (5-Year)
-120.516
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0188
200-day SMA
Sell
Level
$0.0009
Bollinger Bands (100)
Sell
Level
-0.0084 - 0.0116
Chaikin Money Flow
Sell
Level
-5.8M
20-day SMA
Sell
Level
$0.0076
Relative Strength Index (RSI14)
Sell
Level
44.5074
ADX Line
Sell
Level
37.9818
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$0.0031
MACD (12, 26)
Buy
Level
0.0052
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
26.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, NMRD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NMRD average analyst price target in the past 3 months is --.
-
Where Will Nemaura Medical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nemaura Medical, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Nemaura Medical, Inc.?
Analysts are divided on their view about Nemaura Medical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nemaura Medical, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Nemaura Medical, Inc.'s Price Target?
The price target for Nemaura Medical, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NMRD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nemaura Medical, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NMRD?
You can purchase shares of Nemaura Medical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nemaura Medical, Inc. shares.
-
What Is The Nemaura Medical, Inc. Share Price Today?
Nemaura Medical, Inc. was last trading at $0.0001 per share. This represents the most recent stock quote for Nemaura Medical, Inc.. Yesterday, Nemaura Medical, Inc. closed at $0.0000 per share.
-
How To Buy Nemaura Medical, Inc. Stock Online?
In order to purchase Nemaura Medical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NMRD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NMRD
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
NMRD
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
NMRD
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
--
-31.87%
Return on assets
--
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Dec
23
Estimated Next Earnings Date
Mar
24
Balance Sheet
NMRD
Sector
Total cash
--
$26.4M
Short term investments
--
$25.7M
Total assets
--
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 24.71% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 20.67% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is up 19.65% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
